Humana (HUM) Stock Forecast & Price Target

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

• Humana Inc. recently reported strong second-quarter results, beating consensus estimates with earnings per share of $7.61 against an expected $7.27, while revenue grew 26.2% year-over-year to $40.89 billion, demonstrating robust operational performance and demand for its healthcare services.
• The stock is currently trading at $400.70, which is near the average analyst price target of $403.91, suggesting that the current valuation may be fair or slightly undervalued relative to Wall Street's expectations for the company's future growth.
• Humana Inc. maintains a consistent dividend policy, having recently declared a quarterly dividend of $0.885 per share payable in November 2026, which provides a steady income stream for investors with a current yield of approximately 0.88%.
• Institutional interest in the stock has been increasing, with several major funds such as Braidwell LP and Nykredit A S establishing new positions or significantly boosting their holdings in the second quarter, indicating growing confidence among professional investors.
• The company has a relatively low beta of 0.74, meaning its stock price tends to be less volatile than the overall market, which can make it a more stable addition to a diversified portfolio during periods of market uncertainty.